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Edited by Veli-Pekka LehtoAbstract A gene encoding a novel serine protease designated as
Harobin is cloned and identiﬁed from a sea snake venom gland
bacteriophage T7 library. It has 265 amino acids and shares
50–70% similarity to terrestrial snake serine proteases. In addi-
tion to the 12 conservative Cys, it has three more Cys residues
that may contribute to its higher enzymatic stability. Harobin
is expressed in Pichia pastoris and puriﬁed.
Recombinant Harobin exhibits an amidolytic activity, and spe-
ciﬁcally degrades Aa, Bb-chain of ﬁbrinogen. It functions as a
deﬁbrase both in vitro and in vivo, and reduces thrombosis. Har-
obin prolongs the coagulation time and the bleeding time of mice
and reduces the ﬁbrinogen levels of rats as well. Meanwhile,
intravenous injection of Harobin leads to the reduction of blood
pressure in SHR rats. It results from the ability of Harobin that
cleaves angiotensin I and release bradykinin from plasma kinin-
ogen in vitro and in vivo. These data suggest that Harobin is a
novel deﬁbrase and has a potential to be an agent for the therapy
of thrombosis and hypertension.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Snake venoms, especially from crotalidae and viperidae fam-
ilies, are abundant in proteolytic enzymes. According to the
diﬀerence of the enzymatic active site, these proteases are di-
vided into two groups: serine protease and metalloprotease.
Both of them can interact with at least one sort of coagulation
factors or the other protein components in plasma and cleave
speciﬁc peptide bond in their substrates. These substrates are
including coagulation factor II, V, IX, X, plasminogen, protein
C, kininogen and ﬁbrinogen, etc. [1]. Among these venom pro-
teases, some hydrolyze N-terminal end of ﬁbrinogen releasing
ﬁbrinopeptide A or B or both resulting in the formation of ﬁ-
brin. Such an activity resembles that of thrombin and thus is
named thrombin-like enzyme (TLE). Some degrade the Aa-,
Bb- or both chains of ﬁbrinogen at the C-terminus making it*Corresponding author. Address: Department of Biochemistry and
Molecular Biology, College of Life Sciences, Peking University,
Beijing 100871, China. Fax: +86 10 62756174.
E-mail address: gj@pku.edu.cn (J. Gu).
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ase [2]. Some protease can cleave kininogen releasing bradyki-
nin or kallidin, which is a strong vasodilator and has ability to
reduce blood pressure [3]. These protease are regarded as ki-
nin-releasing enzyme or kininogenase [4].
Generally, each of these proteases exhibits only one speciﬁc
enzyme activity. However, up to now, six multifunctional pro-
teases that possess double enzymatic activities have been
reported, including cratalase from Crotalus adamanteus,
KN-BJ from Bothrops jararaca, ﬂavovilase from Trimeresurus
ﬂavoridis (habu), b-ﬁbrinogenase from Tremeresurus mucro-
squamatus, halyse from Agkistrodon halys blomhoﬃi and
Jerdonase from Tremeresurus jerdonii [5]. The former three
are kinin-releasing and ﬁbrinogen clotting enzyme and the
later three are kinin-releasing and ﬁbrinogenolytic enzymes.
Their enzymatic characteristics have been elucidated but their
physiological functions in experimental animals have not been
fully investigated.
Up to now, most of venom serine proteases characterized are
from the terrestrial snakes [6,7]. Venom serine proteases from
sea snake are seldom reported in the literature. We here report
a novel serine protease from sea snake venom. This protease,
named Harobin, are expressed in yeast and characterized. It
exerts antithrombotic activity by cleaving ﬁbrinogen. Further-
more, Harobin cleaved high molecular weight (HMW) kinino-
gen, angiotensin I and angiotensin II, led to reduced blood
pressure in hypertensive rats. The results demonstrate that
Harobin may have a potential application in the therapy of
thrombosis and hypertension.2. Methods
2.1. Cloning and preparation of recombinant Harobin
Sea snake Lapemis hardwickii was from the coast area of Guangxi
province of the People’s Republic of China. Venom gland was taken
and subjected to the extraction of total RNA. mRNA was prepared
using mRNA Puriﬁcation Kit (Amersham Pharmacia). Following
the protocols of OrientExpress Oligo(dT) cDNA synthesizing Kit
(Novagen) and T7 Select packaging Kit (Novagen), a T7 phage display
library was constructed. Human ﬁbrinogen (Sigma) was used as a bait
to screen the library. A positive clone was identiﬁed after screening.
The gene was cloned and sequenced.
The mature enzyme gene of Harobin (without the signal peptide
and the pro-peptide) was cloned into P. pastoris expressing vector
pPIC9K (Invitrogen) at the sites of XhoI and EcoRI. The recon-
structed vector was transformed into GS115 by electroporation after
linearized by SalI. Expression of recombinant enzyme was performed
according to the instruction by manufacturer (Invitrogen). Yeast ex-
pressed Harobin was puriﬁed with Benzamidine-Sepharose CL-6B
column (Amersham Biosciences, USA) using modiﬁed method by
De´bora [8].blished by Elsevier B.V. All rights reserved.
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Ten micrograms of puriﬁed wild type or mutated recombinant Har-
obin were mixed with 0.15 mM of the substrate N-p-tosyl-Gly-Pro-
Arg-p-nitroanilide (Sigma, USA) in 30 mM Tris–HCl buﬀer (pH
8.0), and incubated at 37 C for 10 min. The amount of p-nitroaniline
released was determined by measuring the changes in absorbance at
405 nm. One unit of amidolytic activity was deﬁned as the amount
of enzyme needed to hydrolyze 1 lmol substrate per min. Appropriate
amount of the enzyme was incubated with diﬀerent concentration of
substrates ranging from 20 lM to 200 lM, the enzyme reaction was
plotted in a Lineweaver–Burk manner to obtain the Michaelis constant
Km.
Arginine esterase activity was measured as described by Yabuki
et al. [9], using N-p-tosyl-L-arginine methylesterase (TAME, Sigma)
as a substrate. The absorbance change was monitored at 247 nm for
10 min.
The optimal pH and temperature for the amidolytic activity of Har-
obin was determined at pH range between 4 and 9, and diﬀerent tem-
peratures (25, 35, 45, 55, 65, 75, and 85 C), respectively. For optimal
pH assay, Harobin was dissolved in either citrate buﬀer (30 mM, pH
4–6) or Tris–HCl buﬀer (30 mM, pH 7–9) and preincubated at room
temperature for 2 h. For optimal temperature assay, Harobin was dis-
solved in Tris–HCl buﬀer (pH 8.0). The enzyme was preincubated at
each temperature for 15 min and the reaction was performed for
10 min to measure its amidolytic activity.
PMSF, EDTA and DTT were used to inhibit the enzyme activity of
Harobin. One micrograms of Harobin was incubated with the indi-
cated concentration of inhibitors in 0.4 ml 30 mM Tris buﬀer, amido-
lytic activity was measured.
Fibrinogen clotting activity was measured as described previously
[10]. The time of coagulation of 0.4 ml human ﬁbrinogen (2 mg/ml,
Sigma product) in 50 mM Tris–HCl (pH 8.0) was determined after
2 lg Harobin were added.
The ﬁbrinogenolytic activity was determined by incubating 5 lg
ﬁbrinogen with 0.5 lg Harobin in 20 ll Tris–HCl buﬀer (pH 8.0) at
37 C. An aliquot was taken at 15 min, 30 min, 3 h, 12 h, 18 h, 24 h
and 40 h intervals, respectively, and analyzed on SDS–PAGE.
Fibrinolytic activity was assayed using the ﬁbrin plate technique
[11].2.3. Cleavage of angiotensin I
Fifty microliters of angiotensin I (1 mg/ml) was incubated with 10 lg
Harobin in Hepes buﬀer (50 mM, pH 7.5) at 37 C for 3 h. The mixture
was then analyzed by HPLC (Bio-Rad Bio-Sil ODS-5S C18 column).
HPLC was run for 35 min in a linear gradient of 0–75% solvent B
(95% acetonitrile containing 0.1% triﬂuoroacetic acid (TFA)) with
5% acetonitrile/0.1% TFA (solvent A) as the starting and equilibration
eluent. The ﬂow rate was set at 1 ml/min. Peak fractions were moni-
tored at UV 214 nm and collected. Amino acid sequences were ana-
lyzed by ABI Precise 491 Protein/Peptide Sequencer.2.4. Cleavage of single chain HMW kininogen
Five micrograms of single chain HMW kininogen (from human
plasma, The Enzyme Research Laboratory) was incubated at 37 C
with 0.2 lg Harobin in a total volume of 20 ll buﬀer (50 mM Tris–
HCl, pH 8.0) for various time intervals. The proteolytic products were
resolved on SDS–PAGE. For the assay of released kinin, the above
reacting mixtures were subjected to HPLC. Each peak fraction was
collected and sequenced.2.5. Animals and animal models
Male Sprague–Dawley (SD) rats, spontaneously hypertensive rats
(SHR) and male Balb/c mice were obtained from the Vitalriver Exper-
imental Animals Center, Beijing, China. All animals were speciﬁc path-
ogen free (SPF). They were bred at the animal center of Peking
University. Procedures involving animals and their care were con-
ducted in accordance with the guidelines for the use of animals in bio-
chemical research.
For tail thrombus model, mice were injected intravenously
of drugs. Thirty minutes later, 300 mg/kg of carrageenan (Sigma,
Co) was subcutaneously injected to induce thrombus. The length
of infarction was measured after 48 h according to the literature
[12].For the measurement of ﬁbrinogen, 1 ml citrated blood was col-
lected from the carotid artery of rats before administration of drug
and 6 h later, plasma was prepared by centrifugation and used for
the measure of ﬁbrinogen following the protocols of the manufacturer
(Shanghai Suntech. Co.).
For arterio-venous shunt model, it was performed according to the
method of Umetsu and Sanai [13]. Male SD rat (270–310 g) was anes-
thetized with sodium pentobarbital and ﬁxed in the supine position. A
cervical incision was made in the midline to expose the left carotid ar-
tery and right jugular vein. A 20 cm long polyethylene tube with a 6 cm
long silk thread ﬁxed in its lumen was ﬁlled with physiological saline.
One end of the tube was inserted into the right jugular vein and tied.
Harobin (400 lg/kg), heparin (50 IU/kg) or physiological saline
(2 ml/kg) was injected from the other end of the tube. The proximal
side of the left carotid artery was clamped to block the blood ﬂow tem-
porarily, while the free end of the tube was inserted into the artery and
tied. The clamp was released and the blood ﬂow through the tube was
conﬁrmed. After 15 min, the silk thread was removed from the tube
and its wet weight was immediately measured. The dry weight was
measured after 24 h at 37 C.
For vena cava model, the method described by Reyers et al. [14] was
used. Brieﬂy, 50, 200 lg/kg Harobin, 0.5 lg/kg deﬁbrase (from agkis-
trodon halys ussuriensis emelinov, Beijing Institute of Biological Prod-
ucts, China) or saline was injected from the tail venous just before
the surgery. After anesthetization, the abdomen was opened, the vena
cava was isolated and tied just caudally to the left renal vein and the
incision closed. Six hours later, animals were re-anesthetized, abdom-
inal incision was reopened. When thrombus appeared, it was removed
from the segment, blotted on ﬁlter paper. The wet weight of the throm-
bus was immediately measured. Its dry weight was measured after 24 h
at 37 C.
For the hemorrhagic activity assay, mice were killed 24 h after i.p
administration of 5 mg/kg Harobin and checked for subcutaneous
hemorrhage.
For the clotting time (CT) measurements, a drop of whole blood was
added to a glass slide and stirred up every 30 s with a dried needle until
ﬁbrin appeared. The clotting time was recorded in minutes. Bleeding
time (BT) of mice was measured by a modiﬁcation of the method de-
scribed by Kung et al. [15].2.6. In vivo hypotension assay
Blood pressure was assayed by the method as described previously
[16]. Male SHR rats (250–300 g) were grouped randomly and anesthe-
tized with sodium pentobarbital. The right carotid artery were cannu-
lated with polyethylene tube and attached to a pressure transducer
(Model YPJ01). The blood pressure was recorded on a RM6240 sys-
tem (Chengdu Keyi Factory). Harobin (2 mg/kg), captopril (1 mg/kg)
or saline was injected from the femoral vein. After the measurement
of blood pressure, rats were killed and blood was collected. The level
of angiotensin II in the blood was measured by radioimmunoassay
kit (North Biotechnology Research Institute, Beijing).2.7. Statistical analysis
All data was expressed as the mean ± S.D. Student’s t-test was used
to assess the statistical diﬀerences. P < .05 was considered to be statis-
tically signiﬁcant.3. Results
3.1. Cloning of Harobin
One phage clone from a sea snake venom gland bacterio-
phage T7 library was identiﬁed after screening using ﬁbrinogen
as bait. The gene was then cloned and designated as Harobin.
It had an open reading frame of 795 nucleotides coding for 265
amino acid residues (GenBank accession AY835844, Fig. 1A).
It was homologous to terrestrial snake serine enzymes, sharing
78% similarity with kallikrein-phi4 from Philodryas olfersii
[17], 63% similarity with mucroﬁbrase from Trimeresurus
mucrosquamatus [18], VSP-3 (Venom serine protease 3) from
Trimeresurus gramineus [19] and Pallabin from Gloydius halys
J. He et al. / FEBS Letters 581 (2007) 2965–2973 2967[20], 62% with CPI-enzyme-2 from Gloydius ussuriensis [21],
60% with calobin from Gloydius ussuriensis [22], 58% with
Tsv-Pa from Trimeresurus stejnegeri [23] and PA-BJ from
Bothrops jararaca [24], 48% with Ancrod from Calloselasma
rhodostoma [25], respectively, indicating that Harobin was a
new member of the serine protease family (Fig. 1B). A putative
signal peptide of 18 residues was predicted according to the
method by Nielsen [26]. The pre-zymogen also had a proposed
pro-peptide of 15 amino acid residues (19–33aa). The predicted
molecular mass of mature enzyme (34–265aa) was 25414 Da.
Based on the sequence similarity, we deduced that the catalytic
triad residues were common to serine proteases. They were
His74, Asp119 and Ser212. Three putative N-glycosylation
sites in Asn-Xaa-Ser/Thr, a Ser and a Thr residue as putative
O-glycosylation sites were identiﬁed in the protein through
the analysis using CBS Prediction Server, which was a online
tool and convenient for the analysis of glycosylation site in
protein [27]. Interestingly, this enzyme contained 15 Cys resi-
dues, among which 12 residues were identical to other venom
serine proteases (Fig. 1B). Most of snake venom serine prote-
ases, including TLE [18,20,28], ﬁbrino(geno)lytic serine prote-
ase [29,30], plasminogen activators [31,32] and so on, had sixFig. 1. Sequence analysis. (A) Gene sequence and deduced amino acid seque
was underlined. The translation stop codon was indicated by asterisk. S
glycosylation sites, respectively. The sequence data had been submitted to
alignment. Three conserved critical catalytic sites were highlighted by asterisk
of the serine proteases were indicated as capital C and C 0 under the aligneddisulﬁde bonds which were critical for the maintenance of pro-
tein structure.
3.2. Harobin was a thermostable serine protease
To characterize its biological function, recombinant Haro-
bin was successfully expressed in P. pastoris (Fig. 2A) and eas-
ily puriﬁed by column chromatograph (Fig. 2B). The
molecular weight of Harobin on SDS–PAGE was as deduced
as about 25 kD. Since Harobin shared high homology with
known serine proteases from terrestrial snake venom, we ﬁrst
determined if it had enzymatic activity. Harobin was incubated
with N-p-tosyl-Gly-Pro-Arg-p-nitroanilide or TAME, respec-
tively. The results showed that Harobin had an amidolytic
activity and no arginine esterase activity. The amidolytic activ-
ity was about 8.3 ± 0.3 U/mg protein with a Michaelis constant
Km of 0.39 mmol/L, which was higher than naturally puriﬁed
deﬁbrase from terrestrial snake venom (Table 1). The optimum
conditions for enzyme activity were pH 8.0 and 65 C
(Fig. 2C). The eﬀect of the known serine protease inhibitors
on the amidolytic activity of Harobin was evaluated. As shown
in Fig. 2D, PMSF inhibited the enzyme activity nearly 100%,
while EDTA did not aﬀect at all, indicating that Harobinnce of Harobin. Signal sequence was denoted in boldface. Pro-peptide
olid and open diamonds indicate putative N-glycosylation and O-
the GenBank with the accession number AY835844. (B) Sequence
s. Twelve identical cysteine residues and three diﬀerent cysteine residues
sequence, respectively.
Fig. 1 (continued)
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deoxidize disulfate-bond so that it inhibited disulfate-bond
containing serine protease. Deﬁbrase and Calobin were inhib-
ited 80% by 10 mM DTT [33,34], while Harobin was not
aﬀected at the same concentration, indicating that Harobin
was more stable than other six-disulfate-bond serine protease.
To conﬁrm the notion, we made mutation in Harobin. Two of
the additional three Cys in Harobin (106 Cys-Val, 152 Cys-Ser)
were mutated and expressed in P. pastoris. The activity of wild
type and mutant was compared. Harobin mutant was more
sensitive to DTT and less stable in 65 C (Fig. 2D). It demon-
strated that 106 Cys and 152 Cys participated in the formationof disulfate-bonds and were required for the stability of the
enzyme. Furthermore, the amidolytic activity of Harobin in
30 mM Tris–HCl buﬀer maintained for six months at 4 C
without distinct decrease (Data not shown), indicating that
Harobin was a higher stable protease.
3.3. Harobin functioned as a deﬁbrase in vitro and in vivo
Since Harobin was cloned as a ﬁbrinogen binding protein
and identiﬁed to be a serine protease, it was expected to be a
deﬁbrase. Its ﬁbrino(gen)lytic activity was ﬁrst tested
in vitro. It showed that Harobin digested Bb-chain of ﬁbrino-
gen ﬁrst and then the Aa-chain. The intensity on the c-chain of
Fig. 2. Expression and activity analysis of Harobin. (A) Expression of Harobin in P. pastoris GS115. Supernatants from the cell culture of clones
were resolved on SDS–PAGE. Lane M: protein markers; Lane 1: parental GS115; Lane 2–6: diﬀerent clones. (B) Aﬃnity chromatography on
Benzamidine-Sepharose CL-6B column (left panel). The elution C was resolved on SDS–PAGE (right panel). (C) Eﬀects of pH and temperature on
the amidolytic activity of Harobin and Deﬁbrase. Symbols: m pH optimum of Harobin; j temperature optimum of Harobin; d temperature
optimum of Deﬁbrase. (D) Eﬀect of inhibitors on the amidolytic activity of Harobin and Harobin mutant (106 Cys-Val, 152 Cys-Ser).
Table 1
Comparison of enzymatic activity between Harobin and deﬁbrase
Enzyme activity (U/mg)
Harobin Deﬁbrase
Amidolytic activity 8.3 1.5
Arginine esterase activity <0.01 <0.01
TLE activity 0 1250
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ﬁbrinogen Aa-, Bb-chain, indicating that the Aa-chain orFig. 3. Analysis of ﬁbrino(geno)lytic activity of Harobin. (a) Cleavage pattern
plasma was incubated with 0.5 lg Harobin in 20 ll Tris buﬀer (pH 8.0) at 37
C0 and Lane C24 represent ﬁbrinogen alone at 37 C for 0 h or 24 h. Lane M
Harobin on ﬁbrin plate. Twenty microliters of puriﬁed Harobin (0.1 mg/ml) w
presence of 5 ll, 2 U/ml human plasminogen (A) or in the absence of pl
plasminogen solution (D) and the same quantity of plasminogen plus 2 ll, 1Bb-chain of ﬁbrinogen was cleaved to smaller pieces that were
close to the c-chain size. Finally, the y-chain of ﬁbrinogen was
digested at 18 h and ﬁbrinogen was cleaved to 42 kD fragment.
There was no band corresponding to ﬁbrinogen on SDS–
PAGE at 40 h, suggesting that it was completely degraded
by Harobin (Fig. 3a). As to the speciﬁcity of the enzyme, we
tested its cleavage ability on BSA and found that it did not
cleave BSA. Harobin had no ﬁbrinogen clotting ability and
the coagulation of ﬁbrinogen by thrombin was signiﬁcantly re-
tarded when ﬁbrinogen was incubated with Harobin before
addition of thrombin (data not shown). Fibrinolytic activityof ﬁbrinogen by Harobin. Five micrograms of ﬁbrinogen from human
C for 15 min, 30 min, 3 h, 12 h, 18 h, 24 h and 40 h, respectively. Lane
: molecular weight markers. (b) Detection of the enzymatic activity of
as dropped onto the ﬁbrin plate and incubated at 37 C for 6 h in the
asminogen (B). As controls, 20 ll Tris–HCl buﬀer (C), 5 ll, 2 U/ml
U/ml urokinase (E) were used.
Table 2
Eﬀect of Harobin on mice tail thrombosis (n = 10)
Groups Dose (lg/kg) Length of thrombus (mm)
Saline – 16 ± 8
Deﬁbrase 0.5 3 ± 2*
Harobin 50 4 ± 2*
Harobin 200 0**
*P < 0.05.
**P < 0.001 vs. saline treated groups.
Table 3
Eﬀect of Harobin on the wet weight of thrombus in vena cava model
(n = 10)
Groups Dose (lg/kg) Wet weight of
thrombus (mg)
Inhibition
rate (%)
Saline – 31 ± 7.3 –
Deﬁbrase 0.5 20.5 ± 3.6* 34
Harobin 50 18.2 ± 2.1* 41
Harobin 200 11.4 ± 5.0** 63
*P < 0.05.
**P < 0.001 vs. saline treated groups.
Table 4
Eﬀect of Harobin on the wet weight of thrombus in arterio-venous
shunt model (n = 10)
Dose Wet weight of thrombosis (mg)
Saline – 41.5 ± 8
Heparine 50 IU/kg 22.1 ± 4.9**
Harobin 400 lg/kg 43.3 ± 5.4
**P < 0.001 vs. saline treated groups.
2970 J. He et al. / FEBS Letters 581 (2007) 2965–2973was assayed using ﬁbrin plate method. It showed that addition
of Harobin led to the formation of a clear hollow (Fig. 3b).
The size of the clear hollow kept unchanged even in the pres-
ence of plasminogen, suggesting that Harobin was not a plas-
minogen activator.
We next addressed whether Harobin could function as a
deﬁbrase and had antithrombotic eﬀect in vivo. Three animal
models were established and used for the tests. Injection ofTable 5
Eﬀect of Harobin on coagulation time (CT) and bleeding time (BT) on mice
Groups Dose (lg/kg) CT (min) Prolo
Saline – 2.41 ± 0.47 –
Deﬁbrase 0.5 3.81 ± 0.61** 52.4
Harobin 50 3.50 ± 0.39* 39.44
Harobin 200 4.22 ± 0.75** 68.13
*P < 0.05.
**P < 0.001 vs. saline treated groups.
Table 6
Eﬀect of Harobin on the plasma level of ﬁbrinogen of rats after 6hr of treat
Groups Dose (lg/kg)
Saline –
Deﬁbrase 0.5
Harobin 50
Harobin 200
*P < 0.05.
**P < 0.001 vs. saline-treated groups.Harobin signiﬁcantly decreased the length of tail thrombus
at the concentration of 50 lg/kg, similar to the eﬀect by com-
mercial deﬁbrase in mouse tail thrombosis model (Table 2). In
the vena cava model of rats, Harobin caused the wet weight of
thrombus decrease by 41% at concentration of 50 lg/kg, and
by 63% at the concentration of 200 lg/kg (Table 3). The pro-
portion of wet weight to dry weight of thrombus was 27%
approximately. In the arterio-venous shunt model of rats, Har-
obin had no eﬀect on the wet weight of thrombus at concentra-
tion of 400 lg/kg, while heparin, the positive control, could
inhibit 50% of the wet weight of thrombus at the concentration
of 50 IU/kg (Table 4). The eﬀect of Harobin on the hemor-
rhagic system was also evaluated. The clotting time and bleed-
ing time of mice were prolonged signiﬁcantly by Harobin
(Table 5), the level of ﬁbrinogen of rats was also decreased sig-
niﬁcantly (Table 6). However, Harobin did not show hemor-
rhagic activity in mice at a concentration of 5 mg/kg (data
not shown), indicating it was safe as a therapeutic agent.
3.4. Angiotensin I and kininogen were the substrates of Harobin
It had been suggested that deﬁbrase from snake might had
the ability to reduce blood hypertension [16]. The eﬀects of
Harobin on blood pressure were therefore investigated. Injec-
tion of Harobin into SHR rats caused a signiﬁcant blood pres-
sure drop at a concentration of 2 mg/kg (Fig. 4A). Reduction
of blood pressure started 30 min after injection of Harobin and
lasted at least for 4 h. The change of systolic blood pressure
(SBP) was demonstrated in Table 7.
To explore the mechanism of its anti-hypertensive eﬀect, we
addressed whether angiotensin I and kininogen were the sub-
strates of Harobin. When kininogen was incubated with Har-
obin, the disappearance of kininogen coupled with the
formation of the major fragment of 58 kDa was similar to that
of kallikrein (Fig. 4B). The products after reaction were fur-
ther evaluated by reverse-phase HPLC. One of the released
peptides was identiﬁed as bradykinin (data not shown). Incu-
bation of angiotensin I with Harobin resulted in the formation
of four major peptide fragments. The peptides were sequenced,
respectively. They were His-Leu, Asp-Arg-Val-Tyr, Ile-His-
Pro-Phe, and Asp-Arg-Val-Tyr-Ile-His-Pro-Phe (correspond-
ing to the four major peaks in Fig. 4C). The result suggested(n = 10)
nged CT (%) BT (min) Prolonged BT (%)
3.5 ± 1.13 –
4.43 ± 0.83* 26.57
4.61 ± 0.54* 31.71
5.37 ± 1.32** 53.43
ment (n = 10)
Fibrinogen (g/L) Reducing rate (%)
2.17 ± 0.12 —
1.62 ± 0.11** 25
1.72 ± 0.11** 21
1.3 ± 0.32** 40
Fig. 4. Eﬀect of Harobin on hypertension and its mechanism. (A) A typical example of blood pressure change in SHR rats after treatment of
Harobin (2 mg/kg). (B) SDS–PAGE analysis of kininogen cleaved by Harobin. 5 lg single chain HMW kininogen (from human plasma) were
incubated at 37 C with 0.2 lg Harobin in a total volume of 20 ll Tris–HCl buﬀer (50 mM, pH 8.0) for various time intervals. Lane K0: kininogen
alone; Lane 20 min 1 h 12 h represent the time of kininogen cleaved by Harobin. Lane C0 represents kininogen cleaved by kallikrein; Lane H:
Harobin alone. Lane M: molecular weight markers. (C) Analysis of angiotensin I cleaved by Harobin. Angiotensin I (1 mg/ml) was incubated with
10 lg Harobin in 50 ll Hepes buﬀer (50 mM, pH 7.5) at 37 C for 3 h. The reaction mixtures were then analyzed by HPLC. Peak fractions were
collected and sequenced. (a) represented angiotensin I alone, (b) represented angiotensin I after digestion by Harobin. The labeled peaks indicated
four major proteolytic fragments from angiotensin I.
Table 7
Eﬀect of Harobin on the SBP of SHR rats (n = 8)
Groups Dose
(mg/kg)
Before i.v.
(mmHg)
4 h after i.v.
(mmHg)
Saline – 242 ± 52 227 ± 40
Captopril 1 260 ± 10 151 ± 15**
Harobin 2 241 ± 45 161 ± 35*
*P < 0.05.
**P < 0.001 vs. before treatment.
Table 8
Eﬀect of Harobin on the level of plasma angiotensin II of SHR rats
(n = 8)
Groups Dose (mg/kg) Angiotensin II (pg/ml)
Saline – 368 ± 44
Captopril 1 172 ± 39**
Harobin 2 246 ± 79*
*P < 0.05.
**P < 0.001 vs. saline-treated groups.
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sequently cleaved to two fragments by Harobin. We further
tested if such reaction occurred in vivo. The level of angioten-
sin II in the plasma was signiﬁcantly reduced after the injection
of Harobin (Table 8). It suggested that angiotensin II was the
target of Harobin in vivo.4. Discussion
In this study, a novel sea snake serine protease that targets
ﬁbrinogen, angiotensin and kininogen is described. To our
knowledge, this is the ﬁrst report of isolation, cloning and
characterization of a ﬁbrino(geno)lytic and kinin-releasing ser-
ine protease from sea snake venom.
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Cys besides their highly conservative catalytic sites. However,
the three additional Cys residues in Harobin are very unique
and may contribute greatly to the enzyme stability. 106 Cys
and 152 Cys were selected to mutate because these two are
more close to the conservative Cys and may disturb the normal
disulfate-bonds. The mutation leads to the instability of the
enzyme (Fig. 2D). Further studies on its crystal structure will
highlight its relationship between the structure and function.
Nevertheless, the ﬁnding of Harobin enriches the knowledge
of the family of serine protease.
Harobin functions as a deﬁbrase in vitro and in vivo. It di-
gests ﬁbrinogen eﬃciently in vitro (Fig. 3a). Bb-chain of the
ﬁbrinogen is degraded ﬁrst followed by the degradation of
Aa-chain. This digestion pattern is consistent to that by Tm-
VIG [16]. It is interesting to show that c-chain is degraded as
well after 18 h incubation with Harobin. Digestion of c-chain
of ﬁbrino(gen) by deﬁbrase has been seldom reported. It might
be one of the diﬀerences between the serine protease from ter-
restrial and sea snake. The antithrombotic activity of Harobin
has been evaluated in three animal models. Mice tail thrombus
induced by carageenan is a peri-venous thrombus model and
rat vena cava thrombus is a deep venous thrombus model.
Harobin shows the same eﬀects on antithrombus as natural
puriﬁed deﬁbrase does in both animal models (Fig. 4), but
the amount of Harobin is about 100-folds to that of Deﬁbrase.
This is because Harobin has no TLE activity though it pos-
sesses higher amidolytic activity than Deﬁbrase (Table 1).
The mechanism of antithrombus by Harobin can be explained
by that it degrades ﬁbrinogen or ﬁbrin, and leads to the de-
crease of blood viscosity, thus prevents the formation of
thrombus or dissolves the existed thrombus. The antithrombus
eﬀect is not due to the activation of plasminogen (Fig. 3b).
Harobin does not aﬀect the thrombus in the arterio-venous
thrombus model (Table 4). The structure of thrombus formed
in the model is similar to that of white thrombus in vivo model.
This model is widely used for the evaluation of anti-platelet
drugs [13]. It has been suggested that the inability of the drug
in this model can be explained no eﬀect on the aggregation of
the platelet. Therefore, the failure of Harobin in this model
suggests that it has no eﬀect on the aggregation of the platelet.
It is interesting to show that Harobin signiﬁcantly reduced
the hypertension of SHR rats (Fig. 4A). Since some peptides
from snake venom are able to inhibit the activity of angioten-
sin converting enzyme (ACE) [35]. We ﬁrst exam whether Har-
obin is an ACE inhibitor. It turns out that Harobin does not
aﬀect ACE (data not shown). We then test the eﬀects of Har-
obin on angiotensin I and kininogen, both of which are impor-
tant factors regulating blood pressure. Angiotensin I is ﬁrst
cleaved to angiotensin II and the latter is further cleaved to
two tetrapeptides by Harobin in vitro and in vivo (Fig. 4B,
C). Angiotensin II is hypertensive peptide while the tetrapep-
tide is not. Cleavage of angiotensin II to small peptides could
be one way that Harobin reduces blood pressure. On the other
hand, Harobin has inherent kallikrein-like activity, it can
release bradykinin from plasma kininogen in vitro. This
kallikrein-like activity is especially intriguing since a-ﬁbrino-
genases like ancrod does not show such a speciﬁcity against
kininogen [16]. Bradykinin is a strong vasodilator, this could
be another way that Harobin regulate the blood pressure. To-
gether with the factor that Harobin is a deﬁbrase to degrade
the ﬁbrinogen, we conclude that anti-hypertension eﬀect ofHarobin at least results from the following three independent
ways. (1) It functions as a deﬁbrase that decreases the concen-
tration of blood ﬁbrinogen leading to the alteration of blood
rheology. (2) It degrades angiotensin I and angiotensin II to
lower the concentration of angiotensin II; (3) It works as kal-
likrein to cleave kininogen and release bradykinin that pro-
motes vasodilatation.
Ancrod and batroxobin are all TLE puriﬁed from venom for
clinical usage. Harobin has no TLE activity, but its antithrom-
botic activity is equivalent to naturally puriﬁed deﬁbrase. The
unique structure features and the abilities to digest ﬁbrinogen,
angiotensin and kininogen with higher stability suggest that
Harobin is a novel serine protease. It holds a potential to be
an antithrombosis and hypertension agent.
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